<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01874340</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457B2203</org_study_id>
    <secondary_id>2012-004019-29</secondary_id>
    <nct_id>NCT01874340</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis</brief_title>
  <official_title>A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of AIN457 versus placebo in patients with relapsing
      multiple sclerosis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated early based upon development of another anti-IL17 fully human monoclonal
    antibody with better potential for treating MS patients
  </why_stopped>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Number of New Gadolinium [Gd]-Enhancing T1-weighted Lesions</measure>
    <time_frame>Months 3, 4, 5, 6</time_frame>
    <description>Due to early termination this trial was not powered for efficacy no statistical analysis was performed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized Relapse Rate</measure>
    <time_frame>6 Months</time_frame>
    <description>Due to early termination this trial was not powered for efficacy no statistical analysis was performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Unique Active Lesions (CUAL)</measure>
    <time_frame>Months 3, 4, 5, 6</time_frame>
    <description>Due to early termination this trial was not powered for efficacy no statistical analysis was performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Volume of T2-weighted Lesions</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>Due to early termination this trial was not powered for efficacy no statistical analysis was performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Particpants With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>6 months</time_frame>
    <description>Number of particpants with Adverse events as a measure of safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>AIN457 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 low dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be administered intravenously. Approximately 105 patients will be randomized to placebo (65 in Stage 1 and 40 in Stage 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 middle dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 high dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered at predefined visits over the 6-month treatment phase.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIN457</intervention_name>
    <description>AIN457 will be administered at predefined visits over the 6-month treatment phase.</description>
    <arm_group_label>AIN457 low dose</arm_group_label>
    <arm_group_label>AIN457 middle dose</arm_group_label>
    <arm_group_label>AIN457 high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Multiple Sclerosis according to 2010 revised McDonald criteria

          -  Disease duration of 10 years or less

          -  At least one relapse in the last year

          -  EDSS score 0 to 5.0 at entry

        Exclusion Criteria:

          -  Active chronic disease of the immune system other than multiple sclerosis

          -  History of malignancy within the past 5 years

          -  Active systemic bacterial, viral or fungal infections

          -  Previous treatment with more than one class of multiple sclerosis therapies except for
             previous treatment with glatiramer acetate and interferon-beta(s)

          -  Any medically unstable condition

          -  Unable to undergo MRI scans or repeated blood tests

          -  Pregnant or nursing females

          -  Women of child-bearing potential must use reliable forms of contraception

          -  Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>JIhlava</city>
        <zip>586 33</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>556-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>93-121</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>127018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bilbao</city>
        <state>Pais Vasco</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atakum / Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Romania</country>
    <country>Switzerland</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2013</study_first_submitted>
  <study_first_submitted_qc>June 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2013</study_first_posted>
  <results_first_submitted>April 13, 2015</results_first_submitted>
  <results_first_submitted_qc>May 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 1, 2015</results_first_posted>
  <last_update_submitted>May 14, 2015</last_update_submitted>
  <last_update_submitted_qc>May 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Relapsing Multiple Sclerosis</keyword>
  <keyword>AIN457</keyword>
  <keyword>Secukinumab</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Relapsing Remitting Multiple Sclerosis</keyword>
  <keyword>Autoimmune Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Demyelinating Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AIN457 15 mg/kg</title>
          <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
        </group>
        <group group_id="P2">
          <title>AIN457 7 mg/kg</title>
          <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
        </group>
        <group group_id="P3">
          <title>AIN457 3 mg/kg</title>
          <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Matching placebo will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AIN457 15 mg/kg</title>
          <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
        </group>
        <group group_id="B2">
          <title>AIN457 7 mg/kg</title>
          <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
        </group>
        <group group_id="B3">
          <title>AIN457 3 mg/kg</title>
          <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Matching placebo will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.8" spread="7.73"/>
                    <measurement group_id="B2" value="34.5" spread="8.64"/>
                    <measurement group_id="B3" value="35.5" spread="9.71"/>
                    <measurement group_id="B4" value="34.0" spread="9.30"/>
                    <measurement group_id="B5" value="33.5" spread="8.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Number of New Gadolinium [Gd]-Enhancing T1-weighted Lesions</title>
        <description>Due to early termination this trial was not powered for efficacy no statistical analysis was performed</description>
        <time_frame>Months 3, 4, 5, 6</time_frame>
        <population>Due to the early termination of the study and just one patient completing treatment as planned, no statistical analyses could be performed for the efficacy endpoints defined in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 15 mg/kg</title>
            <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 7 mg/kg</title>
            <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
          <group group_id="O3">
            <title>AIN457 3 mg/kg</title>
            <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Number of New Gadolinium [Gd]-Enhancing T1-weighted Lesions</title>
          <description>Due to early termination this trial was not powered for efficacy no statistical analysis was performed</description>
          <population>Due to the early termination of the study and just one patient completing treatment as planned, no statistical analyses could be performed for the efficacy endpoints defined in the protocol.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Relapse Rate</title>
        <description>Due to early termination this trial was not powered for efficacy no statistical analysis was performed</description>
        <time_frame>6 Months</time_frame>
        <population>Due to the early termination of the study and just one patient completing treatment as planned, no statistical analyses could be performed for the efficacy endpoints defined in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 15 mg/kg</title>
            <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 7 mg/kg</title>
            <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
          <group group_id="O3">
            <title>AIN457 3 mg/kg</title>
            <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Relapse Rate</title>
          <description>Due to early termination this trial was not powered for efficacy no statistical analysis was performed</description>
          <population>Due to the early termination of the study and just one patient completing treatment as planned, no statistical analyses could be performed for the efficacy endpoints defined in the protocol.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Combined Unique Active Lesions (CUAL)</title>
        <description>Due to early termination this trial was not powered for efficacy no statistical analysis was performed</description>
        <time_frame>Months 3, 4, 5, 6</time_frame>
        <population>Due to the early termination of the study and just one patient completing treatment as planned, no statistical analyses could be performed for the efficacy endpoints defined in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 15 mg/kg</title>
            <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 7 mg/kg</title>
            <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
          <group group_id="O3">
            <title>AIN457 3 mg/kg</title>
            <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Combined Unique Active Lesions (CUAL)</title>
          <description>Due to early termination this trial was not powered for efficacy no statistical analysis was performed</description>
          <population>Due to the early termination of the study and just one patient completing treatment as planned, no statistical analyses could be performed for the efficacy endpoints defined in the protocol.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Volume of T2-weighted Lesions</title>
        <description>Due to early termination this trial was not powered for efficacy no statistical analysis was performed</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>Due to the early termination of the study and just one patient completing treatment as planned, no statistical analyses could be performed for the efficacy endpoints defined in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 15 mg/kg</title>
            <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 7 mg/kg</title>
            <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
          <group group_id="O3">
            <title>AIN457 3 mg/kg</title>
            <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Volume of T2-weighted Lesions</title>
          <description>Due to early termination this trial was not powered for efficacy no statistical analysis was performed</description>
          <population>Due to the early termination of the study and just one patient completing treatment as planned, no statistical analyses could be performed for the efficacy endpoints defined in the protocol.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Particpants With Adverse Events as a Measure of Safety and Tolerability</title>
        <description>Number of particpants with Adverse events as a measure of safety and tolerability</description>
        <time_frame>6 months</time_frame>
        <population>The safety set consists of all subjects who received at least one dose of study medication. Subjects will be analyzed according to the treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 15 mg/kg</title>
            <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 7 mg/kg</title>
            <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
          <group group_id="O3">
            <title>AIN457 3 mg/kg</title>
            <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Particpants With Adverse Events as a Measure of Safety and Tolerability</title>
          <description>Number of particpants with Adverse events as a measure of safety and tolerability</description>
          <population>The safety set consists of all subjects who received at least one dose of study medication. Subjects will be analyzed according to the treatment received.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Fatal Seriuos Aderse Event (SAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The safety set consists of all subjects who received at least one dose of study medication. Subjects were analyzed according to the treatment received.</desc>
      <group_list>
        <group group_id="E1">
          <title>AIN457 15 mg/kg</title>
          <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
        </group>
        <group group_id="E2">
          <title>AIN457 7 mg/kg</title>
          <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
        </group>
        <group group_id="E3">
          <title>AIN457 3 mg/kg</title>
          <description>AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Matching placebo will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis doesn not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (i.e. data from all sites) in the clinical trial or disclosure of the trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to early termination this trial was not powered for efficacy no statistical analysis was performed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

